Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.

Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. Abstract Text:

Robert F Storey,Steen Husted,Robert A Harrington,Stanley Heptinstall,Robert G Wilcox,Gary Peters,Mark Wickens, Emanuelsson,Paul Gurbel,Peer Grande,Christopher P Cannon,Robert F Storey,Steen Husted,Robert A Harrington,Stanley Heptinstall,Robert G Wilcox,Gary Peters,Mark Wickens, Emanuelsson,Paul Gurbel,Peer Grande,Christopher P Cannon,

OBJECTIVES: In a substudy of DISPERSE (Dose confIrmation Study assessing anti-Platelet Effects of AZD6140 vs. clopidogRel in non-ST-segment Elevation myocardial infarction)-2, we compared the antiplatelet effects of AZD6140 and clopidogrel and assessed the effects of AZD6140 in clopidogrel-pretreated patients. BACKGROUND: Clopidogrel, in combination with aspirin, reduces cardiovascular events in patients with acute coronary syndromes (ACS). However, patients with poor inhibition of platelet aggregation with clopidogrel may be less well protected. AZD6140 is a reversible oral P2Y(12) receptor antagonist that has been studied in ACS patients in comparison with clopidogrel (DISPERSE-2 study). METHODS: Patients were randomized to receive either AZD6140 90 mg twice a day, AZD6140 180 mg twice a day, or clopidogrel 75 mg once a day for up to 12 weeks in a double-blind, double-dummy design. One-half the patients allocated AZD6140 received a 270-mg loading dose. Patients randomized to receive clopidogrel were given a 300-mg loading dose unless they had already been treated with clopidogrel. Adenosine diphosphate-induced platelet aggregation was assessed by optical aggregometry on day 1 and at 4-week intervals. RESULTS: AZD6140 inhibited platelet aggregation in a dose-dependent fashion and both doses achieved greater levels of inhibition than clopidogrel (e.g., 4 weeks, 4-h postdose [mean (+/-SD)]: clopidogrel 64% [+/-22%], AZD6140 90 mg 79% [+/-22%], AZD6140 180 mg 95% [+/-8%]. AZD6140 also produced further suppression of platelet aggregation in patients previously treated with clopidogrel. CONCLUSIONS: AZD6140 exhibited greater mean inhibition of platelet aggregation than a standard regimen of clopidogrel in ACS patients. In addition, AZD6140 further suppressed platelet aggregation in clopidogrel pretreated patients.

Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. Publishing Authors By Initials

RF Storey,S Husted,RA Harrington,S Heptinstall,RG Wilcox,G Peters,M Wickens,H Emanuelsson,P Gurbel,P Grande,CP Cannon,RF Storey,S Husted,RA Harrington,S Heptinstall,RG Wilcox,G Peters,M Wickens,H Emanuelsson,P Gurbel,P Grande,CP Cannon,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Journal of the American College of Cardiology

VOLUME: 50

Page Numbers: 1852-6

Journal Abbreviation: J. Am. Coll. Cardiol.

ISSN: 1558-3597

DAY: 23

MONTH: 10

YEAR: 2007

Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8301365

Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.

AFFILIATION: Cardiovascular Research Unit, University of Sheffield, Sheffield, United Kingdom. r.f.storey@sheffield.ac.uk

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Am Coll Cardiol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes Related Publications

• A Na+ channel mutation linked to hypokalemic periodic paralysis exposes a proton-selective gating pore.
• Amino acid residues affecting drug pump function in Candida albicans--C. albicans drug pump function.
• Analogical reasoning in working memory: resources shared among relational integration, interference resolution, and maintenance.
• Aneurysmal bone cyst of the paediatric shoulder girdle: a case series and literature review.
• Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28.
• Characterization of three classes of membrane proteins involved in fungal azole resistance by functional hyperexpression in Saccharomyces cerevisiae.
• Cognitive errors, anxiety sensitivity, and anxiety control beliefs: their unique and specific associations with childhood anxiety symptoms.
• Cortical mapping of genotype-phenotype relationships in schizophrenia.
• Current trends in computational inference from mass spectrometry-based proteomics.
• Differences in tropism and pH dependence for glycoproteins from the Clade B1 arenaviruses: implications for receptor usage and pathogenicity.
• First recanalization of a coronary artery chronic total obstruction in an 11-year-old child with Kawasaki disease sequelae using the CROSSER catheter.
• Frances Ashcroft: 2007 Walter B. Cannon physiology in perspective lecture.
• Gender differences in aspirin use among adults with coronary heart disease in the United States.
• Heterozygosity and functional allelic variation in the Candida albicans efflux pump genes CDR1 and CDR2.
• Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention.
• Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
• Lipid-independent Pleiotropic Effects of Statins in the Management of Acute Coronary Syndromes.
• Maintenance of AV synchrony in a small child utilizing two pacemakers and the triggered VVT mode: triggered pacing in small children.
• Mineral Trioxide Aggregate but not Light-cure Mineral Trioxide Aggregate Stimulated Mineralization.
• Predisaster trait anxiety and negative affect predict posttraumatic stress in youths after hurricane Katrina.
• Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia.
• Promoter choice for retroviral vectors: transcriptional strength versus trans-activation potential.
• Restoring federal commitment to basic nuclear medicine research.
• Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients.
• Self-report of attenuated psychotic experiences in a college population.
• Senate appropriators restore funding for basic nuclear medicine research at DOE.
• Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice.
• The association of race and ethnicity with disease expression in male US veterans with rheumatoid arthritis.
• The course of neurocognition and social functioning in individuals at ultra high risk for psychosis.
• The relationship between performance and fMRI signal during working memory in patients with schizophrenia, unaffected co-twins, and control subjects.